| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Fmoc-L-Lys-OH-13C6,15N2 does not have a specific biological target as a drug; it is a labeled amino acid derivative. The Fmoc group protects the amino group during peptide synthesis. The compound is used to synthesize isotope-labeled peptides for mass spectrometry-based protein quantification.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may affect a drug's pharmacokinetics and metabolic properties, it is a cause for concern [75].
Fmoc-L-Lys-OH-13C6,15N2 is not evaluated for in vitro biological activity as a drug; it is a labeled building block for peptide synthesis. The labeled version is used for analytical and proteomics purposes and does not have intrinsic pharmacological activity. |
| ln Vivo |
Fmoc-L-Lys-OH-13C6,15N2 is not administered as a therapeutic agent and does not have intrinsic in vivo pharmacological activity. It is used in the synthesis of labeled peptides for research applications.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Fmoc-L-Lys-OH-13C6,15N2 as a drug target. As a labeled amino acid derivative, it is used in peptide synthesis. The compound is characterized by its isotopic purity and chemical purity.
|
| Cell Assay |
There are no specific in vitro cellular assays for Fmoc-L-Lys-OH-13C6,15N2 as a pharmacologically active compound. As a building block, it is used in the chemical synthesis of peptides, which are then used in cellular assays.
|
| Animal Protocol |
There are no specific in vivo animal studies for Fmoc-L-Lys-OH-13C6,15N2 as a pharmacologically active compound. It is used in the synthesis of labeled peptides for research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fmoc-L-Lys-OH-13C6,15N2 are not applicable, as it is a chemical building block rather than a drug. The compound is not intended for administration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Fmoc-L-Lys-OH-13C6,15N2 is not reported, as it is a research compound used in peptide synthesis. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-243.
|
| Additional Infomation |
Fmoc-L-Lys-OH-13C6,15N2 is a stable isotope-labeled, Fmoc-protected lysine derivative used as a building block for solid-phase peptide synthesis and quantitative proteomics. It is available for research purposes only.
|
| Exact Mass |
476.24
|
|---|---|
| CAS # |
850080-89-6
|
| Related CAS # |
Fmoc-L-Lys (Boc)-OH;71989-26-9
|
| PubChem CID |
71309439
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.566
|
| LogP |
5.455
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
34
|
| Complexity |
684
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)OC(=O)[15NH][13CH2][13CH2][13CH2][13CH2][13C@@H]([13C](=O)O)[15NH]C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
UMRUUWFGLGNQLI-OYSAUITLSA-N
|
| InChi Code |
InChI=1S/C26H32N2O6/c1-26(2,3)34-24(31)27-15-9-8-14-22(23(29)30)28-25(32)33-16-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,21-22H,8-9,14-16H2,1-3H3,(H,27,31)(H,28,32)(H,29,30)/t22-/m0/s1/i8+1,9+1,14+1,15+1,22+1,23+1,27+1,28+1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonyl(15N)amino)-6-[(2-methylpropan-2-yl)oxycarbonyl(15N)amino](1,2,3,4,5,6-13C6)hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
